Parenteral (injectable), ophthalmic, nasal and inhalation routes are categorically outside the dietary supplement definition under US DSHEA Section 201(ff) (which restricts supplements to tablet/capsule/powder/softgel/gelcap/liquid ingestion) and equivalent definitions in EU Directive 2002/46/EC, UK MHRA, Health Canada NHPR, Australia TGA Listed Medicines, Japan PMDA and Korea MFDS. Products administered by these routes are drugs regardless of ingredient composition. Compliant US pathways for sterile-format supplement-adjacent products include FDA New Drug Application (full pharmaceutical authorisation), Section 503A patient-specific compounding via state-licensed pharmacy meeting USP <797> Pharmaceutical Compounding — Sterile Preparations (2023 revision tightens BUD, environmental monitoring, personnel qualification, with Category 1/2/3 BUD scaling), or Section 503B FDA-registered Outsourcing Facility with cGMP-equivalent compliance. USP <800> Hazardous Drugs governs occupational exposure controls. IV vitamin clinics typically operate via 503A or 503B compounded supply under state medical board oversight with physician supervision and clinic-level adverse-event reporting. EU GMP Annex 1 (2023 revision) is the global benchmark for sterile manufacturing introducing the Contamination Control Strategy as integrated organising framework, tightened cleanroom Grade A/B/C/D classification, Grade A unidirectional airflow specification, barrier technology preference (isolators preferred for new design), operator intervention minimisation, media fill discipline and continuous viable/non-viable particle monitoring. Recurrent commercial failure mode is brand-owner expansion from oral supplement portfolio into IV-clinic supply, nasal spray or inhalation with retained supplement marketing — triggering FDA Warning Letter and EU national enforcement.

Regulatory anchors